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The use of an appropriate control group in human research is essential in investigating the level of a pathological disorder. This
study aimed to compare three alternative sources of control lung tissue and to determine their suitability for gene and protein
expression studies. Gene and protein expression levels of the vascular endothelial growth factor (VEGF) and gelatinase families
and their receptors were measured using real-time reverse transcription polymerase chain reaction (RT-PCR) and immunohisto-
chemistry. The gene expression levels of VEGFA, placental growth factor (PGF), and their receptors, fms-related tyrosine kinase 1
(FLT1), and kinase insert domain receptor (KDR) as well as matrix metalloproteinase-2 (MMP-2) and the inhibitors, tissue inhi-
bitorofmatrixmetalloproteinase-1 (TIMP-1)and TIMP-2were signiﬁcantlyhigher inlungcancer resections.Thegeneexpression
level of MMP-9 was signiﬁcantly lower in the corresponding samples. Altered protein expression was also detected, depending on
the area assessed. The results of this study show that none of the three control groups studied are completely suitable for gene and
proteinstudies associatedwith theVEGFandgelatinase families, highlightingtheneed forresearchers tobeselective inwhichcon-
trols they opt for.
1.Introduction
Inordertodeterminethepresenceandlevelofapathological
disorder, an appropriate control is essential to use as a stan-
dard baseline of the normal condition. In animal experi-
ments, controls are relatively easy to obtain, but in many
human studies this can be problematic especially if the ex-
periments involve vital organs such as lung, heart, and kid-
ney. Due to these short comings, researchers often have to
ﬁnd alternative sources of normal tissue. The decision to use
control tissue from a “nonnormal” source is not ideal and
should only be considered as a last resort. If researchers have
to use this source of tissue, it is critical that they choose an
appropriate group. Thus, the aim of this study was to com-
pare several alternative sources of control lung and to deter-
minetheirsuitabilityforgeneandproteinexpressionstudies.
Areviewofthepublishedliteratureshowsthatspecimens
fromlungcancerresectionsareusedfrequentlyascontrolsin
respiratory research in a wide range of conditions including
bronchiolitis obliterans syndrome (BOS), chronic obstruc-
tive pulmonary disease (COPD), bacterial infection, and
idiopathic pulmonary ﬁbrosis [1–4]. Lung cancer resections
are readily available and easy to obtain; however, this
source of control tissue potentially has circulating mediators
released due to the presence of lung cancer.
WhileusingfreshorfrozentissueisidealforRNAquality,
this is not always possible. Improvements in RNA extraction
technology have allowed us to extract RNA from formalin-
ﬁxed paraﬃn-embedded tissue, opening up the possibility of
usingarchivedsamples.Havingaccesstomultiple,alternative
sourcesofcontroltissuewillallowinvestigatorstochoosethe
best representative for their study condition. We aimed to
compare and validate three alternative sources of control
lung tissue including neoplastic tissue, biopsies from stable
post-lung-transplantation patients, and archived formalin-
ﬁxed tissue from pneumothorax patients.
We have selected speciﬁc lung injury biomarkers relating
to the VEGF family including vascular endothelial growth2 The Scientiﬁc World Journal
factor A (VEGFA), placental growth factor (PGF), and their
receptors, fms-related tyrosine kinase 1 (FLT1), kinase insert
domain receptor (KDR), as well as the gelatinases, matrix
metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their
inhibitors, tissue inhibitor of matrix metalloproteinase-1
(TIMP-1) and -2 (TIMP-2).
VEGFisexpressedinmultiplecelltypesinlungincluding
muscle, epithelial lining, macrophages, and endothelial cells
[5, 6]. It is highly expressed during lung development [7],
and its upregulation during maturity is associated with the
presence of lung disease such as oedema [8], emphysema
[9], and the development of PGD after transplantation [10].
Increased VEGF expression has also been reported in lung
cancer tumours in association with angiogenesis [11]a n d
activated macrophages [12]. PGF is a member of the VEGF
family and is expressed in the human placenta under normal
conditions [13] but is upregulated in certain pathological
conditions such as wound healing, pulmonary emphysema,
and tumour formation [9, 14, 15]. The receptors FLT1 and
KDR mediate the eﬀects of both VEGF and PGF and have
beenshowntobesimultaneouslyupregulatedinthepresence
of lung disease [7, 8, 16]. MMP-2 and MMP-9 have been im-
plicated following lung transplant remodelling and injury
[17] as well as having pathological roles in inﬂammation,
cancer, and cardiovascular disease [18, 19]. MMPs are also
involved in many normal processes including embryonic
development, morphogenesis and tissue remodeling, and
wound healing [20, 21]. TIMP-1 and -2 are important en-
zymesinregulatingthebalanceofMMPs,andadisparitycan
lead to pathological remodelling.
These biomarkers are important for detection of early
pathological changes in lung structure and function includ-
ing the presence of primary graft dysfunction (PGD) and
BOS in lung transplantation.
The aim of this study, therefore, was to determine the
suitability of three alternative sources of control tissue deri-
ved from fresh as well as formalin-ﬁxed tissue and to assess
the basal gene and protein expression levels for these speciﬁc
lung injury biomarkers.
2. Methods
2.1. Patients and Sample Collection
2.1.1. Lung Cancer Resection. Samples were obtained from
lung cancer patients undergoing lung resection (n = 29)
where sections were screened to exclude those containing
local tumour, severe emphysema, ﬁbrosis, and vascular inva-
sion. Samples were only collected from patients with a pri-
mary tumour, with no lymph node involvement or distant
metastasis as detailed in the pathologist’s histopathology re-
port. These samples included 4 nonsmokers.
2.1.2. Stable Post-Lung-Transplant Biopsy. Biopsies were ob-
tained from bilateral lung transplantation patients where 38
biopsies were collected during diagnostic and surveillance
bronchoscopies. Samples ranged from 1 week to over 2 years
following transplantation, and, of these, 26 were classiﬁed as
stable.
2.1.3. Pneumothorax Archived Tissue. T h eﬁ n a lg r o u pw e r e
patients admitted with pneumothorax (n = 15) where
samples were obtained retrospectively from archived tissue
blocks, less than 2 years old. These samples had previously
been ﬁxed in formalin and embedded in paraﬃn.
All experimental procedures were conducted with the
approval of The Prince Charles Hospital Research and Ethics
Committee (EC2639) with written informed consent from
the subjects. Lung cancer resection samples and lung trans-
plantation biopsies were collected in RNAlater (Ambion,
Calif, USA) for RNA extraction and 10% buﬀered formalin
for histological analysis.
2.2. Isolation of RNA and cDNA Synthesis. Total RNA was
isolated from biopsies and lung resections using Trizol
(Ambion, Calif, USA) and samples puriﬁed with the RNeasy
Mini Kit (Qiagen, Australia). RNA was extracted from pneu-
mothorax samples using the RecoverAll Total Nucleic Acid
Isolation Kit (Ambion, Calif, USA) for formaldehyde- or
paraformaldehyde-ﬁxed, paraﬃn-embedded tissues. All
samples were DNase treated (Ambion, Calif, USA) and sub-
sequently analysed on an Agilent Bioanalyzer (Agilent Tech-
nologies, Australia) to determine RNA concentration and
quality. First strand cDNA was synthesized from 400ng of
RNA using random primer and AMV Reverse Transcriptase
(Roche, Basel, Switzerland).
2.3. Real-Time PCR. Primers were purchased from Applied
Biosystems (Table 1). Real-time quantitative RT-PCR was
performed using a Rotor-Gene 6000 real-time rotary ana-
lyzer (Corbett Research, Australia) with Universal PCR Mas-
ter Mix containing UNG AmpErase (Applied Biosystems,
USA). The cycling conditions were as follows: cDNA was
denatured at 95◦C for 10min, followed by 40 cycles of 95◦C
for 15s and 60◦C for 60s. A no-template and reverse tran-
scription negative control was included for each primer set.
Threshold cycle (Ct) values from the Rotor-Gene software
version 1.7 (Corbett Research, Australia) were exported to
Microsoft Excel for further analysis. All measurements were
performed in triplicate for each gene, and samples were
quantiﬁed from standard curves, using serial dilutions of a
cDNA pool of all lung samples. GeNorm 3.4 software was
used to determine the most stable reference genes, and all
genes of interest were subsequently normalised to GUSB,
HGPRT, and B2M.
2.4. Immunohistochemical Staining. Lung tissue was ﬁxed in
formalin for at least 48hrs, and processed, and embedded in
paraﬃn, and 4µms e r i a ls e c t i o n sw e r ec u t .P r i o rt ot h ea p -
plication of primary antibodies, the sections were subjected
to antigen retrieval by heating at 95◦C for 20mins in cit-
rate buﬀer followed by blocking endogenous peroxidase by
incubating them in 3% H2O2 for 5min. Nonspeciﬁc binding
was blocked by incubating them in 10% normal horse serum
for 1hr (Vector Lab, Calif, USA). Primary antibodies against
VEGF, PGF (1:200), FLT1, KDR, TIMP-2 (1:200), MMP-2,
TIMP-1 (1:100), and MMP-9 (1:40) were purchased from
Santa Cruz (Calif, USA). Antibodies were applied and then
incubated overnight at 4◦C. Macrophages were identiﬁedThe Scientiﬁc World Journal 3
Table 1: Primer information for Real time PCR.
Gene Full gene name ABI assay ID Category
VEGFA Vascular endothelial growth factor A Hs00173626 m1 Growth factor
PGF Placental growth factor Hs01119262 m1 Signal transduction
FLT1 Fms-related tyrosine kinase 1 Hs01052945 m1 Signal transduction
KDR Kinase insert domain receptor Hs00911692 m1 Cell proliferation and diﬀerentiation
MMP-2 Matrix metalloproteinase 2 Hs00234422 m1 Calcium binding
MMP-9 Matrix metalloproteinase 9 Hs00234579 m1 Calcium binding
TIMP-1 Tissue inhibitor of matrix metalloproteinase 1 Hs00171558 m1 Protein metabolism and modiﬁcation
TIMP-2 Tissue inhibitor of matrix metalloproteinase 2 Hs01091319 m1 Protein metabolism and modiﬁcation
GUSB Beta-glucuronidase 4333767T Carbohydrate metabolism
HGPRT Hypoxanthine phosphoribosyltransferase 4333768T Nucleoside, nucleotide, and nucleic
acid metabolism
B2M Beta-2-microglobulin 4333766T Immunity and defence
Table 2: Patient demographics.
Cancer Transplant Pneumothorax
Age 37–81 (median 68) years 22–61 (median 40) years 17–65 (median 24) years
Gender 14 females
15 males
13 females
10 males
3 females
4 males
Diagnosis
Adenocarcinoma (n = 15)
Squamous cell carcinoma (n = 5)
Carcinoid tumour (n = 3)
Large cell carcinoma (n = 3)
Intralobular pulmonary sequestration (n = 1)
Usual interstitial pneumonia (n = 1)
Cryptococcoma (n = 1)
Bilateral lung transplant Pneumothorax
Smoking history Yes (n = 25)
No (n = 4)
Yes (n = 1)
No (n = 25) No (n = 7)
using CD68 (1:200; Dako, Calif, USA). The Vector universal
ABC secondary antibody kit (Vector Lab, Calif, USA) was
used to link the primary antibody to the chromogen and
incubated for 1hr. A positive reaction was detected with
3,3 -diaminobenzidine tetrahydrochloride (Sigma-Aldrich,
Munich, Germany) which produces a brown colour at the
site of the reaction.
2.5. Immunoreactivity Scoring. Images were photographed at
a magniﬁcation of 250x and visualised using the AxioVision
4.7ImageAnalysissystem.Semiquantitativeanalysiswasper-
formed by an independent investigator blinded to the slide
identity. The staining intensity was assessed and scoring re-
cordedinthebronchioleandalveolarliningofthelungtissue
as well as in the inﬂammatory cells including macrophages
and polymorphonuclear leucocytes (PMNs). The intensity
of positive staining was scored as negligible (0), mild (1),
moderate (2), and strong (3).
2.6. Statistical Analysis. Comparison between the three con-
trol groups was determined using a one-way ANOVA with
Tukey’smultiple comparison testforgeneexpression studies,
where statistical signiﬁcance was assumed when P<0.05.
Gene and protein expression was considered at a basal
level when all three groups showed similar expression levels.
If one group diﬀered in expression, this group was excluded
as a control source for the measurement of that particular
biomarker.
3. Results
3.1. Study Population. Patient demographics can be seen in
Table 2. Lung cancer patients had a higher age compared to
either lung transplant or pneumothorax patients.
3.2. Gene Expression Levels. Biopsies from post-lung-trans-
plant patients were grouped into the stable category (n =
26) by an independent assessor. Tissue from lung cancer
resections (n = 29) and pneumothorax patients (n = 15)
were processed in parallel. Intact RNA was successfully ex-
tracted from all lung cancer resection and lung transplant
biopsy tissue; however, assessment of RNA integrity for
the formalin-ﬁxed paraﬃn-embedded pneumothorax tissue
revealedintactRNAforonlysevensamples.Thegeneexpres-
sion level of VEGFA, PGF, and their receptors FLT1 and KDR
as well as MMP-2 and the inhibitors TIMP-1 and TIMP-2
was signiﬁcantly higher in lung cancer specimens compared4 The Scientiﬁc World Journal
to pneumothorax samples and biopsies from lung transplant
patients (P<0.001; Figure 1). The gene expression level
of MMP-9, however, was lower in lung cancer specimens
compared to the other two groups.
Analysis of lung cancer resection tissue from the four
nonsmoking patients compared to the smoking group
showed there was no signiﬁcant diﬀerence between the two
groups in the expression of any of the genes examined (data
not shown).
3.3. Histological Evaluation. When determining pathological
changes in lung function, the bronchial and alveolar lining
and inﬂammatory cell inﬁltrate are considered the most im-
portant area of assessment. Our study found abundant
macrophages in the lung cancer and pneumothorax sections
with clusters situated mostly in the alveolar spaces through-
out the entire section. Some macrophages were also found in
the transplant biopsy but in markedly lower numbers (Fig-
ures 2(a), 2(b),a n d2(c)). PMNs were also found abundantly
in lung cancer though the amount and distribution varied
from sample to sample. Only occasional PMNs were found
in pneumothorax and transplant biopsy samples. Due to this
variability, scoring was not done in PMNs. Protein expres-
sion was, therefore, assessed in the bronchial and alveo-
lar lining as well as in the macrophage inﬁltrate.
3.3.1. Bronchiole. Lung cancer resections had higher expres-
sion levels of TIMP-1 compared to pneumothorax and
transplant biopsies while the level of KDR was higher in both
thelungcancerandtransplantbiopsies.ThelevelsofTIMP-2
werehigherinthetransplantgrouponly.Nodiﬀerenceswere
found in PGF, FLT1, or MMP-9 expression. The expression
of VEGFA and MMP-2 was lower in lung cancer resections
compared to pneumothorax and the transplant biopsy. Rep-
resentative images of bronchial staining can be seen in
Figures 3(a), 3(b),a n d3(c).
3.3.2. Alveolar Lining. All groups had similar expression
levels for most of the proteins analysed except TIMP-1 which
was higher in the lung cancer resection, MMP-2 which was
higher in lung transplant biopsy and VEGFA, which was ele-
vated in pneumothorax samples. Representative images of
alveolar staining can be seen in Figures 3(d), 3(e),a n d3(f).
3.3.3. Macrophages. There was weaker staining of MMP-2
and VEGFA in the transplant biopsies, and the levels of
PGF were found to be lower in lung cancer resections. Rep-
resentative images of macrophage staining can be seen in
Figures 3(g), 3(h),a n d3(i).
The results of the scoring of the immunoreactivity for all
of the antibodies studied are shown in Table 3.
Based on the results, we established a list of biomarkers
that are unsuitable for gene expression and immunohisto-
chemical studies (Table 4). These markers showed altered ex-
pression in lung cancer, transplant biopsies, or pneumotho-
rax samples.
4. Discussion
Obtaining control tissue from completely well patients is dif-
ﬁcult. As a result specimens from “nonnormal” sources are
used frequently as controls in human research. This study
aimed to assess three diﬀerent sources of control lung. We
compared the gene and protein expression of several lung
injury biomarkers important in lung remodelling in cancer
resections, biopsies from stable lung transplantation pa-
tients, and pneumothorax specimens. Samples from cancer
resectionsandbiopsiesfromstablelungtransplantationwere
obtained after surgery and separated into two tubes with
RNAlater for subsequent RNA extraction and formalin for
histological analysis. The pneumothorax samples were ob-
tained from archived formalin-ﬁxed paraﬃn-embedded tis-
sue blocks. Intact RNA was successfully extracted from only
7 of the 15 pneumothorax samples. The number of samples
would need to be increased in future studies to compensate
for the possible failure of RNA extraction methods. The age
of paraﬃn blocks is also one of the main determining factors
ofRNAquality,sofutureextractionwouldbebetterfocussed
on younger tissue blocks. These results should, therefore, be
interpreted with caution as the quality of mRNA extracted is
often poor.
The gene expression level of VEGFA, PGF, and their
receptorsFLT1andKDRaswellasMMP-2andtheinhibitors
TIMP-1 and TIMP-2 was higher in samples from lung can-
cer resections compared to pneumothorax and transplant
biopsysamples.Immunohistochemicalstudiesshowedlower
expressionlevelsofVEGFAandMMP-2inlungcancerresec-
tions compared to pneumothorax and transplant biopsies,
while in contrast TIMP-1 and KDR expression was higher in
lung cancer. This ﬁnding is the opposite to previously pub-
lished ﬁndings showing signiﬁcantly lower gene and protein
expression of all VEGF isoforms in control samples com-
pared to ARDS in a murine model [22] in which the control
group was derived from carefully selected normal lung.
Despite the high gene expression levels of VEGFA, PGF,
FLT1, KDR, MMP-2, TIMP-1, and TIMP-2, only KDR and
TIMP-1 were high at the protein level in the lung cancer
resections. This could be due to the presence of abundant
macrophages and PMNs which might contribute to the
highertotalgeneexpressionlevel.Asecondpossibleexplana-
tion is that these genes are not regulated at a transcriptional
level. There are many studies showing discrepancies between
gene and protein expression which can be attributed to dif-
ferences in gene regulatory mechanisms [23–26]. Posttran-
scriptional processes can be aﬀected by mRNA stability and
changesintranslationaleﬃciency.SomemRNAsarestrongly
retained in the nucleus, which can lead to their levels being
overestimated relative to protein levels [23]. Gene expression
is also representative of the entire lung while protein expres-
sion was assessed separately in the bronchial and alveolar
lining and in inﬂammatory cell inﬁltrate.
VEGFA is known to be upregulated in several forms of
human cancer [11, 27] and is involved in multiple pathways
including remodelling in normal and pathological condi-
tions. The high gene expression in lung cancer specimens is
not unexpected and could be due to an angiogenic responseThe Scientiﬁc World Journal 5
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Figure 1: Quantitative real-time PCR analysis of VEGFA (a), PGF (b), FLT1 (c), KDR (d), MMP-2 (e), MMP-9 (f), TIMP-1 (g), and TIMP-2
(h). Gene expression levels were increased for VEGFA, PGF, FLT1, KDR, MMP-2, TIMP-1, and TIMP-2 in lung cancer (n = 29) compared to
formalin-ﬁxedparaﬃn-embedded(FFPE)tissue(n = 7)andstablelungtransplantbiopsies(n = 26).ThelevelsofMMP-9weresigniﬁcantly
decreased. Results are expressed as mean ± SD. Asterisks indicate P<0.05.6 The Scientiﬁc World Journal
Table 3: Immunoreactivity scores for antibodies in lung derived from cancer resection, transplant biopsy, and pneumothorax.
Antibody
Cancer Transplant Pneumothorax
BL AL MPG BL AL MPG BL AL MPG
V E G F A 0 - 1 0 - 1 2301323
P G F 0 - 10 00 - 10 20 - 10 2
F L T 1 0 - 1 0 - 120 - 1 0 - 120 - 1 0 - 12
K D R 313312 0 - 1 0 - 1 2
M M P - 2 2 0 - 1 2331303
M M P - 9 0 - 10 10 - 10 00 - 10 1
TIMP-1 2-3 2 2 0-1 1 2 0-1 0 2
TIMP-2 0-1 0 1212 0 - 1 02
BL: bronchiole lining.
AL: alveolar lining.
MPG: macrophages.
CD68
Cancer
(a)
Transplant
(b)
Pneumothorax
(c)
Figure 2: Immunohistochemical staining for CD68. The distribution of CD68+ macrophages in lung cancer resection (a), transplant biopsy
(b), and pneumothorax (c). Magniﬁcation 250x.
to the nearby tumour. VEGFA binds both the FLT1 and KDR
receptors though the majority of its eﬀects are mediated
through KDR [28]; hence, an increase in the expression of
VEGFA is likely to be associated with an increase in both
FLT1 and KDR. PGF mediates most of its eﬀects through
the FLT1 receptor and is expressed in the placenta, heart, and
lungs.IthasbeenshownthatneutralisingPGFcanreducethe
inﬁltration of angiogenic macrophages in tumours [29]s oi t
may be an important target in cancer. PGF levels have been
shown to be increased in several forms of cancer including
non-small-cell lung cancer, correlating with tumour stage
[30]. MMP-2 is also upregulated in pathological conditions
including cancer [18, 19] but like VEGFA is also elevated
in normal processes including embryonic development and
tissue remodelling so an increase in lung cancer specimens
could be expected [20, 21]. TIMP-2 binds to the hemopexin-
like domain of pro-MMP-2, and, therefore, an elevation in
MMP-2 is likely to be followed by a corresponding increase
in the levels of its inhibitor. Interestingly the gene expression
levels of MMP-9 were decreased in lung cancer specimens.
MMP-9 has a more speciﬁc role in pathological remodeling,
and gene regulation may be speciﬁc to the tumour region.
TIMP-1 was higher at both the transcriptional and protein
levels in the lung cancer specimens. TIMP-1 complexes with
metalloproteinases by binding to their catalytic zinc cofactor
and is known to act on numerous forms of MMP.
Analysis of the lung tissue from the four nonsmoking
patients showed no signiﬁcant diﬀerence to the smoking
group (data not shown) even though lung cancer in non-
smok ersisdiﬀerentonagenetic,cellular,andmolecularlevel
[31]. This suggests that the gene expression changes analysed
in this study relate to the tumour, not smoking damage per
se.
Our data shows that researchers need to exercise caution
in choosing which group they use as a source of control
tissue. The results of this study raise questions about the
validity of using lung cancer resections as controls. In partic-
ular its use as a control for genes involved in development,
remodeling, and pathological conditions is inappropriate.
There is, however, the possibility that lung cancer resection
tissue could be used in a limited way for immunohistochem-
ical studies particularly if the assessment involves alveolar
lining and macrophage inﬁltrate.
Our study shows that pneumothorax samples and lung
tissue from stable lung transplant patients can be used asThe Scientiﬁc World Journal 7
Table 4: Biomarkers unsuitable for gene and protein expression studies in cancer resection, transplant biopsy, and pneumothorax.
Cancer resection Transplant biopsy Pneumothorax
Gene expression VEGFA, PGF, FLT1, KDR, MMP-2, MMP-9, TIMP-1, TIMP-2 None None
Protein expression
Bronchial lining VEGFA, TIMP-1, KDR, MMP-2 KDR, TIMP-2 None
Alveolar lining TIMP-1 MMP-2 VEGFA
Macrophages PGF MMP-2, VEGFA VEGFA
VEGFA
Cancer
(a)
Transplant
(b)
Pneumothorax
(c)
VEGFA
(d) (e) (f)
PGF
(g) (h) (i)
Figure 3: Representative immunohistochemical staining in the bronchial and alveolar lining and macrophages. The level of VEGFA
expression was diminished in the bronchial lining of cancer resection (a) compared to transplant biopsy (b) and pneumothorax (c). The
alveolar lining shows elevated levels of VEGFA in pneumothorax (f) compared to cancer resection (d) and transplant biopsy (e). The level
of PGF expression was diminished in macrophage inﬁltrate in lung cancer (g) compared to transplant biopsy (h) and pneumothorax (i).
Magniﬁcation 250x.
an alternative to lung cancer resections and is likely to be
a better representative. MMP-2 and VEGFA in the alveolar
area and macrophage inﬁltrate and KDR and TIMP-2 in
the bronchial lining of transplant biopsies are the only ex-
ceptions. Archived formalin-ﬁxed paraﬃn-embedded tissue
is an alternative source provided that the RNA integrity is
maintained, which may require increased numbers of sam-
ples to undergo RNA extraction. Our results highlight the
need for researchers to be careful in selecting appropriate
controls.
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